Disruption of the Cr2 Locus Results in a Reduction in B-1a Cells and in an Impaired B Cell Response to T-Dependent Antigen  by Ahearn, Joseph M et al.
Immunity, Vol. 4, 251±262, March, 1996, Copyright 1996 by Cell Press
Disruption of the Cr2 Locus Results in a Reduction
in B-1a Cells and in an Impaired B Cell Response
to T-Dependent Antigen
Joseph M. Ahearn,*² Michael B. Fischer,*³ deficient in C3 or in earlier components involved in for-
mation of classical pathway C3 convertase, i.e., C2 orDenise Croix,² Siegfried Goerg,³
C4, demonstrated similar defects in their humoral re-Minghe Ma,³ Junrong Xia,³ Xioning Zhou,³
sponses. However, the requirement for complement isRobert G. Howard,§ Thomas L. Rothstein,§
not absolute, as the use of adjuvants or administrationand Michael C. Carroll³
of large doses of antigen (Bitter-Suermann and Burger,³Department of Pathology
1989) may overcome the reduction in efficiency of hu-Harvard Medical School
moral responses due to complement insufficiency.Boston, Massachusetts 02115
Murine follicular dendritic cells (FDCs) and B cells²Department of Medicine
bear two distinct receptors, i.e., mCR1 (CD35; 190 kDa)Division of Rheumatology
(Kinoshita et al., 1985) and mCR2 (CD21; 150 kDa) (Fin-Johns Hopkins School of Medicine
geroth et al., 1989; Kurtz et al., 1990; Molina et al., 1990)Baltimore, Maryland 21205
for activated products of C3 and C4. They are encoded§Departments of Medicine and Microbiology
at a single locus, i.e., Cr2, on chromosome 1. Both geneBoston University School of Medicine
products are organized into multiple repeating struc-Boston, Massachusetts 02118
tures referred to as short consensus repeats (SCRs)
that consist of conserved repeats of 60±70 amino acids
(Fingeroth et al., 1989; Kurtz et al., 1990; Molina et al.,Summary
1990). mCR1 is composed of 21SCRs, a transmembrane
stretch, and a short cytoplasmic tail. In addition to theCovalent attachment of activated products of the third
15 SCRs encoding the mCR2 sequence, it includes sixcomponent of complement to antigen enhances its
unique SCRs on the N-terminal region of the protein.immunogenicity, but the mechanism is not clear. This
While both receptors bind activated products of comple-effect is mediated by specific receptors, mCR1 (CD35)
ment C3 and C4, they differ in ligand binding specificity,and mCR2 (CD21), expressed primarily on B cells and
i.e., mCR1 binds C3b, iC3b, C3d,g, C3d, C4b, and C4d,follicular dendritic cells in mice. To dissect the role of
while mCR2 binds iC3b, C3d,g, and C4d (PramoonjagomCR1 and mCR2 in the humoral response, we have
et al., 1993; Kalli and Fearon, 1994; Molina et al., 1994).disrupted the Cr2 locus to generate mice deficient in
In addition, mCR1 serves as a cofactor in facilitatingboth receptors. The deficient mice (Cr22/2) were found
hydrolysis of C3b to iC3b and C3d,g by the serine prote-to have a reduction in the CD51 population of perito-
ase factor I (Kinoshita et al., 1985; Molina et al., 1994).neal B-1 cells, although their serum IgM levels were
Accordingly, this cofactor role provides a mechanismwithin the range of normal mice. Moreover, Cr22/2
for release of complexes by one receptor (mCR1) andmice had a severe defect in their humoral response
uptake by the other (mCR2).to T-dependent antigens that was characterized by a
Despite the codistribution and structural identity be-reduction in serum antibody titers and in the number
tween mCR1 and mCR2, evidence in vivo supports aand size of germinal centers within splenic follicles.
role for only the latter in the immune response. Pretreat-Reconstitution of the deficient mice with bone marrow
ment of mice with a rat monoclonal antibody (7G6) thatfrom MHC-matched Cr21/1 donors corrected the de-
recognizes both mCR1 and mCR2 blocked the immunefect, demonstrating that the defect was due to B cells
response to both T-dependent (TD) and T-independentthemselves. These results indicate an obligatory role
antigens, whereas a monoclonal antibody that only rec-of B cell complement receptors in responses of the B
ognized mCR1 determinants failed to block (Heyman et
cells to protein antigens.
al., 1990; Gustavsson et al., 1995). Further evidence in
support of a distinct role for mCR2 came from the finding
Introduction that soluble mCR2 also blocks the immune response to
TD antigen (Hebell et al., 1991).
In humans, CR1 and CR2 are encoded by distinct butEvidence has accumulated over the past two decades
closely linked loci on chromosome 1 (Carroll et al., 1988;implicating a crucial role for the complement system
Rey-Campos et al., 1988); each bears a distinct bindingin humoral immune responses. For example, transient
site recognizing C3b, C4b and iC3b, C3d,g, C3d, C4d,depletion of the third component of complement (C3)
respectively. CR1 and CR2 are coexpressed on B lym-in mice before immunization leads to impaired humoral
phocytes and FDC, while CR1 is also found on redresponses (Pepys, 1972). Further characterization of the
cells, polymorphonuclear cells, and phagocytic macro-transiently depleted mice demonstrated a defect in the
phages. In addition, CR1 has cofactor activity for inacti-localization of antigen to germinal centers (Papamichail
vation of C3b and C4b (reviewed by Ahearn and Fearon,et al., 1975; Klaus et al., 1980). Similarly, studies in
1989). On B cells, CR2 is associated with either CR1guinea pigs (Ochs et al., 1983; Boettger et al., 1986;
(Matsumoto et al., 1991) or a complex of CD19, TAPA-1,Bitter-Suermann and Burger, 1989), dogs (O'Neil et al.,
and Leu-13 (Carter et al., 1991; Kansas and Tedder,1988), and humans (Jackson et al., 1979) genetically
1991; Bradbury et al., 1992).
A possible role for the CR2 receptor in human B cell
activation was demonstrated in vitro when it was found*J. M. A. and M. B. F. contributed equally to this manuscript.
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that coligation of the CR2±CD19±TAPA-1±Leu-13 com-
plex and the B cell receptor (BCR) with antibody, i.e.,
anti-CR2 and anti-IgM, respectively, reduced the level
of anti-IgM necessary for cell activation by approxi-
mately 5- to10-fold (Carter and Fearon, 1992). A possible
mechanism for this enhancing effect came from the find-
ing that CD19 is rapidly phosphorylated by tyrosine ki-
nases on activation of the B cell, and it binds the p85
subunit of phosphatidylinositol (PI) 3-kinase (Tuveson
et al., 1993). Thus, it was proposed that the CR2±CD19±
TAPA-1±Leu-13 complex provides a mechanism for co-
stimulation of the B cell when antigen±C3 ligand adducts
are bound by antigen-specific B cells (Carter and
Fearon, 1992; Fearon and Carter, 1995).
To examine the role of mCR1 and mCR2 in the humoral
immune response in vivo, we have used the approach
of gene targeting in embryonic stem (ES) cells to disrupt
the Cr2 locus. Mice homozygous for the disrupted locus
(Cr22/2) were found to have a significant decrease in
peritoneal CD51 B-1 cells and a profound defect in their
antibody response to a TD antigen. The defect could be
repaired by reconstitution with bone marrow from Cr21/1
major histocompatibility complex (MHC)±matched lit-
termates.
Results
Disruption of Cr2 Locus
The Cr2 locus was disrupted by homologous recombi-
nation in ES cells (Koller and Smithies, 1992) as de-
scribed (Wessels et al., 1995). The replacement type
targeting vector (pNT/Cr2), which includes both positive
(neo) and negative (HSV-TK) selection markers, was as-
sembled by insertion of the neo selection marker within
the BamHI site in SCR-10 of the Cr2 coding region (Mol-
ina et al., 1990) (Figure 1A). Thus, the neo coding se-
quence introduces a frameshift mutation and a stop
codon disrupting the coding for mCR1 and mCR2. Fol-
lowing transfection of ES cell line AB1 with 25 mg of
linearized targeting vector, approximately 400 double-
selected colonies were picked into 96-well plates and
expanded for analysis by the technique of RamõÂrez-Solis
et al. (1992). Eight colonies bearing a mutant Cr2 locus
Figure 1. Disruption of the Cr2 Locus by Gene Targeting in Embry-
onic Stem Cells
(A) Partial restriction maps of the wild-type murine Cr2 locus, which
encodes both mCR1 and mCR2, the targeting vector, and the pre-
dicted map of the targeted locus. Assembly of the targeting vector
is described in the Experimental Procedures.
(B) Inheritance of both alleles of the mutant Cr2 gene is demon-
strated by Southern blot analysis of DNA from tail biopsies of off-
spring from breeding brother 3 sister heterozygotes. Genomic DNA
was digested with BamHI and hybridized with probe A as indicated
in (A). The upper band (10 kb) corresponds to the Cr2 targeted allele;
the lower band (8 kb) represents the Cr2 wild-type allele.
(C) FACS analysis of splenocytes of Cr22/2 and wild-type mice dem-
onstrates deficiency in expression of CD35/CD21 (mCR1/mCR2) on
B cells of the former. Splenic MNCs were stained with biotinylated
CD35/CD21 MAb (7E9, anti-mCR1/mCR2) or biotinylated IgG2a (iso-
type control) coupled to streptavidin±PE (data not shown). Data are
gated for lymphocytes. Thick line represents Cr22/2, and thin line
represents wild-type splenocytes (shaded).
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were identified by presence of a 10 kb restriction frag-
ment length polymorphism (RFLP) as predicted (Figure
1A). Of these, six were found to have a normal mode of
40 chromosomes, and one (CR2A3) was microinjected
into blastocysts for generation of chimeric mice. Breed-
ing of chimeric males with parental C57BL/6 females
yielded offspring heterozygous for the mutant Cr2 allele,
based onSouthern blot analysis of tail DNA. Mice homo-
zygous for the mutant allele, i.e., Cr22/2, were generated
by brother±sister mating of heterozygotes (Figure 1B).
Disruption of the Cr2 locus was confirmed by analysis
of spleen cells by immunostaining and flow cytometry
for surface expression of mCR1 and mCR2. Spleens
were removed from wild-type and Cr22/2 mice and either
frozen for cryosections or prepared for fluorescence-
activated cell sorting (FACS) analysis. Splenic sections
from both groups of mice were stained on the same
slide with monoclonal antibodies (MAbs) specific for
mCR1 and mCR2 (7E9) or the mature B cell marker
CD45R (B220). Histologic analysis demonstrated that
both complement deficient and phenotypically normal
mice have well-developed, typical splenic follicles; how-
ever, the Cr22/2 mice express negligible levels of mCR1
and mCR2 on their B cells compared with levels in wild-
type controls (described below in Figure 7). Similar re-
sults were obtained by flow cytometric analysis of
splenic B cells; i.e., negligible difference was observed
when Cr22/2 B cells were stained with 7E9 MAb or IgG2a
isotype-matched control (Figure 1C).
Reduction of Peritoneal CD51 B-1 Cells
Figure 2. Cr22/2 Mice Have a Significant Reduction in Peritonealin Cr22/2 Mice
CD51/IgM1 (B-1a cells)Examination of peripheral blood leukocytes in Cr22/2
Peritoneal leukocytes were isolated from Cr22/2 mice and wild-typeand wild-type mice demonstrated no inherent reduction
littermates by lavage, depleted of macrophages by three rounds ofin either the total cell numbers or the ratios of peripheral
absorption on plastic dishes, and examined by two-color immuno-mononuclear cells to granulocytes (i.e., Cr22/2, 75% 6
fluorescence staining using FACS analysis. Cells with forward and
6%: 25% 6 6%, versus wild-type, 72% 6 6%: 28% 6 side light scatter properties of lymphocytes were analyzed. B-1a
6%), respectively. Similarly, no significant differences cells stained positive for IgM (FITC-conjugated F(ab9)2 fragments of
were found in the numbers of splenic lymphocytes (i.e., GamIgM) and CD5 (PE-conjugated anti-CD5) but negative for CD11b
(PE-conjugated anti-Mac-1). B-1b cells stained positive for IgM andCr22/2, 5.3 3 107 6 2.1 3 107, versus wild-type, 5.2 3
CD11b. B-2 cells stained positive for IgM and expressed CD23 (the107 6 0.2 3 107, for the two groups of mice, nor were
low affinity IgE receptor) butno CD5 or CD11b. Quadrants delineatedany differences found in the ratios of CD4 to CD8 T cells
by squares indicate negative and positive populations of cells as
(i.e., Cr22/2, 13.9% 6 2.8%: 7.4% 6 2%, versus wild- determined by use of isotype controls. The percentages of the total
type, 11.9% 6 3.7%: 6.8% 6 2%), or in the number of gated lymphoid cell population in each quadrant is indicated. Equal
splenic B cells (i.e., Cr22/2, 70.5% 6 6.3% versus wild- numbers of events are plotted for each staining. Results represent
pooled cells from two mice for each group.type, 71.2% 6 5.7%).
In contrast, analysis of peritoneal B-1a and B-1b cells
demonstrated a significant (p < 0.05) reduction in the however, levels of IgG2a (Cr22/2, 560 6 97 mg/ml, versus
percent of B-1a (IgM1, CD51), i.e., 42% 6 10% versus wild-type, 977 6 313 mg/ml, p < 0.05), IgG2b (Cr22/2,
71% 6 4% for Cr22/2 and wild-type, respectively (Figure 704 6 75 mg/ml versus wild-type, 1085 6 355 mg/ml,
2), whereas the B-1b population (IgM1, CD11b1) was p < 0.05), and IgG3 (Cr22/2, 287 6 89 mg/ml versus wild-
approximately the same in Cr22/2 and normal littermates type, 557 6 160 mg/ml, p < 0.01) were significantly lower
(i.e., Cr22/2, 28% 6 4%, versus wild-type, 21% 6 than in normals. To evaluate the humoral response of
7%). The additional immunoglobulin M (IgM)±positive the Cr22/2 mice to TD antigens, deficient mice and wild-
cells in the peritoneum of Cr22/2 mice are CD23-positive type controls were immunized with bacteriophage
or B-2 cells (i.e., Cr22/2 49% 6 15%, versus wild-type,
FX174. Bacteriophage was chosen as a model TD anti-
20% 6 5%) and are significantly increased (p < 0.05). gen because it is highly immunogenic when injected
intravenously in the absence of adjuvants, and a sensi-
tive bacterial neutralization assay can be used to deter-Cr22/2 Mice Have a Severe Defect in Humoral
Response to TD Antigens mine antibody titers. Moreover, guinea pigs, dogs, and
humans deficient in the early components of comple-The serum levels of IgM, IgG1, and IgA were within the
same range as the wild-type controls (data not shown); ment, i.e., C2, C3, or C4, fail to respond to levels
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9833 6 763, versus Cr22/2, 850 6 51; results show mean
anti-phage IgG titer 6 SD measured after 1 week of
secondary challenge).
To gain insight into the nature of the impaired humoral
response, spleens from three mice of both groups, i.e.,
immunized wild-type and Cr22/2 mice, were analyzed by
immunohistology. Both groups of mice were challenged
with antigen again at week 9 and their spleens removed
7 days later for cryosectioning and staining with peanut
agglutinin (PNA), a marker for germinal center (GC) B
cells (Rose et al., 1980). Thus, the extent of the GC
reaction in Cr22/2 and wild-type controls could be deter-
mined by enumerating the number and volumes of PNA1
GC within the splenic follicles. Both nonimmune wild-
type and Cr22/2 mice have equivalent numbers of pri-
mary splenic follicles and relatively few PNA1 GCs,
which presumably represent exposure to environmental
antigens (Figure 4; Table 1). However, by 7 days after
secondary challenge with phage, wild-type animals de-
veloped a prominent GC reaction with >50% of the
splenic follicles containing PNA1 GCs (Figure 4; Table
1). In contrast, the splenic follicles of similarly treated
Cr22/2 mice had significantly fewer and smaller PNA1
GCs (Figure 4; Table 1). The GCs present in Cr22/2 mice
exhibited cross-sectional areas (as determined by mor-
phometric analysis) approximately 10-fold less than that
in the wild-type controls, i.e., mean percent of PNA1
area in white pulp 8 6 2.4 versus 0.7 6 0.7 for wild-type
and Cr22/2 mice, respectively. Thus, the deficiency in
mCR1/mCR2 results in a block in the GC reaction to the
TD antigen FX174.
Figure 3. Cr22/2 Mice Fail to Make an IgG Response to the TD Cr22/2 B Cells Do Not Have an Inherent
Antigen Bacteriophage FX174 Defect in CD40 or BCR Signaling
Cr22/2 (open squares) and wild-type littermates (closed circles) were A possible explanation for defective humoral immunity
injected intravenously with 3 3 107 FX174 on days 0 and 21 and
in Cr22/2 mice is that their B cells have an inherentbled at the time indicated. Levels of anti-phage FX174 antibodies
defect in signal transduction. To determine whether theirwere determined in a neutralization assay as described in the Experi-
B cells could transduce activation signals normally inmental Procedures section. Results are evaluated by a reciprocal
of the dilution required to neutralize 50% of pfu. IgM and IgG were vitro, we compared splenic B cells of the two groups
distinguished on the basis of the sensitivity of the former to 2-ME. of mice in proliferation assays following culture with
Test sera were incubated overnight in 0.1 M 2-ME before assay. All lipopolysaccharide (LPS), goat anti-mouse IgM (Gam-
results are presented as means 6 SD. Asterisks indicate statistical IgM), or soluble CD40L.
significance with p value of <0.05.
No differences were observed between the B cells of
the two groups in their response to LPS over a range
(1.5 3 106 pfu/kg) that are immunogenic in complement of 0.05±25 mg/ml (data not shown). Comparison of the
sufficient controls (reviewed by Bitter-Suermann and responses of Cr22/2 and wild-type B cells following
Burger, 1989). cross-linking with two different concentrations of F(ab9)2
Both mCR1/mCR2-deficient and wild-type control fragments of GamIgM demonstrated no apparent differ-
mice were immunized intravenously with 3 3 107 pfu of ences (Figure 5). Similarly, Cr22/2 B cells responded
phage at day 0 and day 21 and were bled each week normally on treatment with soluble CD40L (a fusion pro-
following the primary immunization. Interestingly, the tein, consisting of the extracellular domain of CD40L
Cr22/2 but not the wild-type controls failed to make normal and CD8a, cross-linked with anti-CD8 MAb) alone or in
primary or secondary humoral responses (Figures 3A combination with interleukin-4 (IL-4) or anti-IgM (F(ab9)2
and 3B). One week following the secondary challenge fragments of GamIgM). Thus, the splenic B cells of
with phage, wild-type mice responded with mean anti- Cr22/2 mice have no apparent defect in signaling via
phage titers of 16,400 (6 6,900) versus 700 (6 600) for LPS, BCR, or CD40. However, these assays would not
Cr22/2 mice. Analysis of the specific IgG titer demon- detect a lack of signaling via the proposed costimulation
strated a negligible secondary response by the Cr22/2 pathway, i.e., CR2±CD19±TAPA-1, since the assays did
mice, i.e., 9,000 (6 400) versus 560 (6 480) mean titers not include coligation of CR2 and BCR.
for wild-type and Cr22/2 mice, respectively. When a 10-
fold larger dose (3 3 108 pfu) of bacteriophage FX174 Repair of the Immune Defect in Cr22/2 Mice
was administered, Cr22/2 mice showed a modest IgG with Wild-Type Bone Marrow
response, although peak responses were still approxi- To test the hypothesis that the defect in the Cr22/2 mice
was due to absence of mCR1/mCR2 on the B cells,mately 10-fold less than wild-type controls (wild-type
Defective Immune Response in Cr22/2 Mice
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Figure 4. The Defect in Antibody Response
to TD Antigens in Cr22/2 Mice Is Character-
ized by a Reduction in the Number and Size
of PNA1 GCs within Splenic Follicles
Seven days following secondary immuniza-
tion with 3 3 107 pfu of bacteriophage FX174,
spleens were harvested and snap frozen and
treated as described in the Experimental Pro-
cedures for immunohistochemical analysis.
Subsequently, sections were incubated for 1
hr at room temperature with PNA coupled to
HRP. Immunostaining identifies splenic PNA1
GC B cells staining in black. Original magnifi-
cation, 103.
Table 1. Comparison of Number and Size (Area) of PNA1 Germinal Centers within Splenic Folicles of Cr22/2, Wild-Type, and Bone
Marrow Chimeras Either Immunized or Nonimmune
Immunized Nonimmune
Genotype Number of Number of Percent PNA1 Number of Number of Percent PNA1
Mouse GCsa Follicles White Pulpb Genotype Mouse GCs Follicles White Pulp
Wild-type 1 12 37 4.6 Wild-type 1 1 22 NDc
2 29 53 8.8 2 3 17 ND
3 19 29 7.8 3 1 8 ND
4 29 44 10.2 4 4 24 ND
22 6 8d 41 6 10d 8 6 2.4d 2.3 6 1.5d 18 6 7d
Cr22/2 1 6 33 0.5 Cr22/2 1 5 43 ND
2 7 35 0.6 2 6 40 ND
3 1 11 0.1 3 0 48 ND
4 7 14 1.7 4 0 45 ND
5 6 3d 23 6 13d 0.7 6 0.7d 2.8 6 3.2d 44 6 3d
Chimeras 1 11 38 2.7
2 17 39 2.5
3 34 54 9.1
4 29 50 6.9
23 6 11d 45 6 8d 5.3 6 3.2d
a Number of GCs based on counting of splenic follicles stained with PNA.
b Areas of PNA1 GCs were determined by morphometric assay.
c ND, not determined.
d Mean 6 SD.
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Figure 5. B Cells of Cr22/2 Mice Have No Inherent Defect in Signal
Transduction via BCR or CD40
Splenic B cells (1 3 106/ml) from Cr22/2 mice and wild-type lit-
termates were purified by complement-mediated lysis of T cells
(90% B2201). B cells were stimulated either with 1 mg/ml or 10 mg/
ml anti-IgM F(ab9)2 of goat anti-mouse IgM (GamIgM) MAb, with
soluble CD40L (a fusion protein, consisting of the extracellular do-
main of CD40L and CD8a, as described in the Experimental Proce-
dures section, that was cross-linked with anti-CD8 MAb in this
assay), with 10 mg/ml anti-IgM F(ab9)2 MAb and soluble CD40L, or
soluble CD40L and 100 IU/ml IL-4.
the deficient mice were reconstituted with bone marrow
(BM) from Cr21/1 MHC-matched littermates. It was ex-
pected that the mature B cells and FDCs would be of
donor and host origin, respectively. FDCs are long lived
and radioresistant and are not thought to be replaced
by donor cells following a BM transplant (Humphrey et
Figure 6. The Defective Immune Response of Cr22/2 Mice Can Beal., 1984) or transplant of splenic tissue (Imazeki et al.,
Corrected by Engraftment of Cr22/2 Mice with Wild-Type Bone1992).
Marrow
BM recipients were bled 2 and 4 weeks after en-
Bone marrow chimeras (Cr22/2 mice that were engrafted with wild-
graftment, and their peripheral blood lymphocytes type bone marrow 4 weeks previously; open triangles), Cr22/2 mice
(PBLs) were analyzed by flow cytometry for coexpres- (open squares), and wild-type littermates (closed circles) were in-
sion of the B cell marker CD19 and mCR1/mCR2 (CD35/ jected intravenously with 3 3 107 FX174 on days 0 and 21 and bled
at the times indicated. Levels of anti-phage FX174 antibodies wereCD21). By week 2, approximately one third of the CD191
determined in a neutralization assay as described in the Experimen-B cells expressed mCR1 and mCR2 (37% of CD191 cells
tal Procedures section and Figure 3. All results are presented asare CD35/CD211), and by week 4, the majority of the
means 6 SD.
circulating CD191 B cells expressed the two receptors
(75.8% of CD191 cells are CD35/CD211).
The humoral response of the BM chimeras was com- immunostaining with MAbs specific for CD45R (B220),
mCR1/mCR2 (7E9), and FDC (FDC-M1) (Figure 7). Stain-pared with that of wild-type and Cr22/2 mice following
immunization with phage antigen at days 0 and 21. Inter- ing of the splenic follicles of wild-type mice with 7E9
resulted in a similar pattern as that seen with B220, asestingly, the BM chimeras made normal primary and
secondary antibody responses, i.e., week 4 mean anti- expected, since mCR1 and mCR2 are expressed on
most mature B cells. However, follicles stained with 7E9phage response of 15,300 6 6,300 (BM chimeras), ver-
sus 16,400 6 6,900 (wild-type), in contrast with that of also included a cluster of intensely staining cells within
the region of the GC not observed with B220. Thesethe unreconstituted Cr22/2 mice, i.e., 700 6 600 (Figures
6A and 6B). The B cell response of BM chimeras was cells were identified as FDCs, as double staining of serial
sections with the FDC specific antibody FDC-M1 (Tewfurther characterized by immunostaining splenic sec-
tions with PNA as described above. Similar numbers et al., 1990) and PNA revealed colocalization of the 7E9
intensely staining pattern and FDC PNA1 GCs. In con-and sizes of PNA1 GCs were observed in the splenic
follicles of BM chimeras as those seen in immune wild- trast, immunostaining of the splenic follicles of BM chi-
meras with 7E9 did not reveal intensively staining cells,type mice (see Figure 4, lower right). Thus, the defect
in the Cr22/2 mice could be repaired by reconstitution even though PNA1 GCs and FDCs could be identified
in these sections. Thus, the secondary splenic follicleswith BM from Cr21/1 mice, suggesting a role for mCR1/
mCR2 on B cells as the cause of defective antibody of BM chimeras included Cr21/1 B cells but Cr22/2 FDCs.
Analysis of the splenic follicles of Cr22/2 mice with 7E9responses.
To confirm that the FDCs of BM chimeras were defi- antibody demonstrated negligible staining, as expected
on the basis of the results from FACS (see Figure 1C),cient in mCR1/mCR2, splenic follicles were analyzed by
Defective Immune Response in Cr22/2 Mice
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Figure 7. Comparison of Splenic Follicles of Wild-Type and Cr22/2 Mice and BM Chimeras (Cr21 BM into Cr22/2 Mice) by Immunohistochemical
Staining
Serial sections of spleens from wild-type or Cr22/2 mice or BM chimeras were single-stained with either biotinylated CD35/CD21 MAb (7E9,
anti-mCR1/mCR2) or biotinylated CD45R MAb (B220) or double-stained with biotinylated FDC M-1 MAb coupled to avidin±AP and HRP±PNA
and were visualized with Fast Blue BB and Naphthol AS±MX±phosphate (blue color) and 3-AEC (red color), respectively. Original magnification,
403.
but a normal pattern of staining with B220 and FDC-M1 deficiency in one of the early components of comple-
ment (classical pathway) (Bitter-Suermann and Burger,antibodies.
1989) results in impaired humoral responses. This en-
hancing effect is presumably due to the covalent attach-Discussion
ment of C3 to antigen (Law et al., 1980; Tack et al.,
1980), as it is first introduced into the nonimmune recipi-It is becoming increasingly apparent that the innate and
adaptive components of the immune system are tightly ent. Thus, the attachment of an activated fragment of C3
to antigen increases its immunogenicity by enhancinglinked. For example, it is well known that inflammation-
inducing adjuvants enhance T cell responses, presum- uptake by specific receptors, i.e., mCR1 and mCR2,
expressed by B cells and FDCs.ably by theactivation of antigen-presenting cells leading
to more efficient uptake of antigen and expression of To begin to clarify the role of complement in the hu-
moral antibody response in vivo, we have used the ap-costimulators such as B7 (Liu and Janeway, 1992). How-
ever, the role of complement in the humoral response proach of gene targeting in ES cells to disrupt the Cr2
locus. Cr22/2 mice were demonstrated to express negli-has been largely overlooked. Previous studies have
shown that depletion in C3 (Pepys, 1972) or genetic gible levels of mCR1 and mCR2 by both FACS analysis
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(Figure 1C) and immunostaining of splenic sections (Fig- 4; Table 1). A similar phenotype has been reported for
mice deficient in CD40 (Castigli et al., 1994) or blockingure 7) with a MAb, 7E9, that binds both receptors. Thus,
Cr22/2 mice provide a murine model for analysis of the of the CD40±CD40L interaction with antibody to CD39
(Foy et al., 1994), and it suggested either a failure tomechanism by which complement is involved in the hu-
moral response. For the balance of the discussion, the receive T cell help or a defect in B cell signaling. Absence
of T cell help is not likely, as mCR1 and mCR2 are nottwo receptors will be discussed as one (mCR1/mCR2),
since they are coexpressed or both deleted in the mod- expressed on T cells. Inherent defects in the signaling
via the BCR and CD40 receptor in the Cr22/2 mice wereels described.
Expression of mCR1/mCR2 in normal mice is primarily ruled out by the in vitro assays (Figure 5). However, the
assays were limited in that they employed saturatinglimited to mature B cells and FDCs; therefore, disruption
of the locus was not expected to affect the number of levels of anti-IgM antibody and CD40L in the absence
of C3 ligand and thus would not have detected the typescirculating mononuclear cells or granulocytes nor the
number of splenic T cells. However, a significant de- of defects (discussed below) that result from deficiency
in mCR1/mCR2.crease in the population of peritoneal B-1a cells was
found. B-1 cells are IgM1/IgDlo and represent the major Two models that are not mutually exclusive have been
proposed to explain the enhancing effect of mCR1/population of B cells found in the peritoneum. Formerly
referred to as Ly-1 B cells, they have been renamed as mCR2 on the antibody response, i.e., antigen trapping
by FDCs and signal transduction by B cells. Uptake ofB-1, and two subgroups, B-1a and B-1b, have been
identified on the basis of expression of CD5 (B-1a) (Kan- antigen by FDCs is considered an essential step in their
activation and in the formation of GCs (Klaus et al.,tor, 1991). While the origin and development of CD51
B-1a cells are not well understood, these cells are 1980; Kosco-Vilbois et al., 1993). FDCs capture immune
complexes via Fc and mCR1/mCR2 receptors (Tew andthought to be a major source of serum antibody (Her-
zenberg et al., 1986). They are also a major source of Mandel, 1979; Szakal et al., 1989). Cr22/2 mice would
be predicted to have an impaired uptake of antigen byantibody to phosphorylcholine (PC) and phosphatidyl-
choline and low affinity autoreactive antibodies (Her- FDCs and therefore a limited ability to form GCs.
The second model proposes that mCR2 enhanceszenberg et al., 1986). Expression of mCR1 and mCR2
by these cells has not been reported, and except for BCR signal transduction by providing a costimulatory
signal via the CR2±CD19±TAPA-1 complex (Carter et al.,the observation that CD19 deficient mice also have a
reduced number of B-1 cells (Engel et al., 1995; Rickert 1988; Carter and Fearon, 1992). In vitro studies in human
B lymphocytes demonstrate that coligation of the BCRet al., 1995), it was not predicted that the Cr22/2 mice
would have a defect in their development. It is possible and CR2±CD19±TAPA-1 complex significantly reduces
the levelof anti-BCR antibody required to induce releasethat maintenance of the B-1a population requires anti-
gen stimulation that is enhanced by signaling via the of free Ca21, activation of PLCg, or cell proliferation.
Coligation is mediated by binding of C3 ligand±antigenCR2±CD19±TAPA-1 complex, as proposed by Rickert
et al. (1995). These results demonstrate that the comple- adducts by the two receptor complexes. The recent
reports that CD192/2 mice also have a defect in B cellment pathway is also involved in maintenance of B-1a
cells. Interestingly, in addition to CD192/2 mice, defi- response to TD antigen favors this model. Thus, the
proposed signaling role of CD19 in the activation ofciency in Bruton's tyrosine kinase (btk2/2) (Kerner et
al., 1995; Khan et al., 1995) or the proto-oncogene vav mature B cells would depend on the binding of C3±
antigen adducts to mCR1/mCR2 receptors for efficient(vav2/2) (Tarakhovsky et al., 1995; Zhang et al., 1995)
also results in a dramatic decrease in peritoneal B-1 coligation of the CR2±CD19±TAPA-1 complex with the
BCR. However, the phenotype of the CD192/2 mice iscells. Reduction in B-1 cells has varying effects on the
level of serum immunoglobulin. For example, btk2/2 more severe than that found in the Cr22/2 mice, and this
might be accounted for by its earlier expression in Bmice express low levels of IgM and IgG3, while CD192/2
mice have decreased levels of IgM. In contrast, vav2/2 cell development.
The reduction in number and size of PNA1 GCs in themice have near normal levels of IgM and IgG. Similarly,
Cr22/2 mice have normal levels of IgM, IgG1, and IgA; Cr22/2 mice could be explained by either of the two
models. However, results from characterization of micehowever, levels of IgG2a, IgG2b, and IgG3 are signifi-
cantly reduced. Moreover, the repertoire of the circulat- with differential expression of mCR1/mCR2 on their B
cells or FDCs would support the signal transductioning antibody might be different from wild-type mice if
specific clones of B-1 cells require mCR1/mCR2 expres- model. First, somatic chimeric mice, which have normal
levels of mCR1/mCR2 on their FDCs but not on their Bsion for their maintenance.
Challenge of the Cr22/2 mice with a TD antigen demon- cells, have a defect in their humoral response similar to
that of the Cr22/2 mice (Croix et al., 1996). In this model,strated a profound defect in both primary and secondary
antibody responses (Figures 3Aand 3B).The impairment the approach of blastocyst complementation in
RAG22/2 embryos was used to generate chimeric miceis in part dependent on the antigen dose, as a 10-fold
increase in antigen did result in a modest increase in that expressed the two receptors on FDCs but not on
B cells. Thus, antigen trapping in these mice would bespecific antibody production. However, the anti-phage
IgG titer remained significantly lower then in wild-type expected to be normal, yet the mice failed to respond
to a TD antigen (NP-KLH).controls. Characterization of the defect by immunostain-
ing of splenic sections revealed an impaired formation In this study, reconstitution of Cr22/2 mice with Cr21/1
bone marrow transplant corrected the immune defectof GCs. Both the number and size of PNA1 GCs were
reduced compared with those in wild-type mice (Figure (Figure 6).The BM chimeric mice have near normal levels
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either end of the PGK±neo gene in vector pNT, which also includesof Cr21/1 B cells, but their FDCs are host derived (Cr22/2).
the negative selection marker PGK±HSV±TK (Tybulewicz et al.,Thus, these chimeric mice make an apparently normal
1991). This effectively introduces the neo gene within the BamHIhumoral response despite the absence of mCR1/mCR2
site of SCR-10 in the mCR2 coding sequence (Molina et al., 1990),
expression on their FDCs. This result demonstrates that resulting in a frameshift and downstream termination codon. Trans-
the defect observed in the humoral response lies at the fection, selection, and screening of ES cells (line AB-1) were per-
formed as described (Wessels et al., 1995), except that ES cellslevel of the B cell and not the FDC and supports the
were maintained on a subclone of Sto feeders (transfected withsecond model. While expression of the two receptors on
leukemia inhibitory factor gene). Clones bearing a targeted Cr2 locusFDCs was not critical for an apparent normal secondary
were identified by Southern blot analysis (10 kb versus 8 kb forresponse, long-term memory, i.e., greater than 10
mutant and wild-type alleles, respectively) following digests of geno-
weeks, was not examined. mic DNA with BamHI and probing with a 39 cDNA probe that hybrid-
The reduction in number and size of PNA1 GCs in the ized outside the region included within the targeting vector (South-
ern, 1975). One clone (CR2A3) was selected for microinjection of dayCr22/2 mice indicates that B cell expression of mCR1/
3.5 embryos (C57BL/6), and the injected embryos were implantedmCR2 is critical at two stages of B cell activation, i.e.,
in the uterus of pseudopregnant females as described previouslyactivation of virgin B cells within the periarteriolar
(Wessels et al., 1995). Male chimeric offspring were bred withlymphoid sheath (PALS) zone and antigen selection
C57BL/6 females to generate offspring heterozygous for the mutant
within the GC. Naive B cells first encounter antigen allele. Offspring with agouti coat color were screened by Southern
within the PALS zone or T cell region of the splenic white blot of tailDNA as described above for ES cells to identify inheritance
of the disrupted Cr2 locus. To generate homozygous deficient mice,pulp (MacLennan, 1994). Expression of mCR1/mCR2
F1 brother 3 sister matings were performed.would be important at this critical stage, especially when
antigen is limiting, as the antigen receptor is usually of
Generation of Bone Marrow Chimeraslow affinity. Thus, coligation of BCR and CR2±CD19±
Bone marrow cells of Cr22/2 mice and wild-type littermates were
TAPA-1 following engagement of antigen±C3 ligand isolated by flushing femurs and tibias with cold medium (DMEM
complex would enhance B cell activation (reviewed by supplemented with 1% bovine calf serum) by using a 26G needle,
Fearon and Carter, 1995). The significant reduction in followed by depletion of erythrocytes with lysis buffer (0.15 M NHCl4,
10 mM KHCO3, 0.1 mM EDTA). Bone marrow cells (5 3 106) weresize of GCs of immunized Cr22/2 mice suggests that
injected intravenously into lethally irradiated (23 650 rads) Cr2-development of the mCR1/mCR2-deficient GC B cells
deficient mice. After 2 and 4 weeks, blood samples of chimeric micehas either slowed or they are dying at an accelerated
were analyzed for mCR1/mCR2-bearing B cells.
rate. An important checkpoint in the development of GC
B cells is antigen selection, as this provides a mecha- Hematology and Measurement
nism to eliminate autoreactive clones that may have of Serum Immunoglobulin
formed during somatic hypermutation (reviewed by Mice were bled from retro-orbital plexus or from the tail vein. Whole
blood was diluted 1:10 in 2% acetic acid, and total white bloodMacLennan, 1994). Antigen is retained within the GC
counts were determined on a hematocytometer. Blood smears wereon the surface of FDCs via FcR and mCR1/mCR2 (Tew
prepared and stained with the Diff-Quik stain set (Baxter Healthcareand Mandel, 1979; Szakal et al., 1989). In the absence of
Corporation, Miami, FL) to count leukocytes. Absolute numbers of
mCR1/mCR2, antigen trapping would be less efficient. each leukocyte population were calculated by multiplying the total
Nonetheless, the BM chimeras described above (Figure leukocyte counts by the percent of total. Serum immunoglobulin
4; Table 1) were capable of forming normal sized GCs, levels were determined by isotype-specific enzyme-linked immuno-
sorbent assay (ELISA) (Southern Biotechnologies, Birmingham, AL).and this probably is explained by trapping of antigen±
The concentration of the individual immunoglobulin isotype wasantibody complexes via FcR. However, in the case of
calculated with a standard curve derived by linear regression of thethe Cr22/2 mice, the absence of mCR1/mCR2 combined
log-transformed concentrations of the isotype standards supplied
with low titer of specific antibody would result in limited with the ELISA kit versus the respective log-transformed ELISA±
trapping of antigen by FDCs. Thus, in the absence of optical density (OD) values.
sufficient antigen, development of B cells within the GC
would be reduced. Flow Cytometric Analysis
Splenic mononuclear cells (MNCs) isolated from spleen cell suspen-In summary, we have found that expression of mCR1/
sions by buoyant density gradient centrifugation (Ficoll-Paque plus,mCR2 is essential in both the humoral response to TD
Pharmacia Biotech, Uppsala, Sweden) were stained with fluoresceinantigens and the maintenance of B-1a cells. The defec-
isothiocyanate (FITC)-conjugated CD45R MAb (B220), biotinylated
tive humoral response of the Cr22/2 mice was character- CD35/CD21 MAb (7E9 or 7G6, provided by Dr. M. Kinoshita, Re-
ized by a reduction in serum antibody and number and search Institute for Microbial Disease, University of Osaka, Japan)
(Kinoshita et al., 1988), FITC-conjugated CD4 (L3T4), or phycoer-size of germinal centers within the splenic follicles. En-
ythrin (PE)-conjugated CD8 (Ly-2). PE-conjugated streptavidin wasgraftmentof bone marrow from wild-type MHC-matched
used to reveal biotin-coupled antibody staining. Adherent peritoneallittermates into the Cr22/2 mice corrected the block in
cells were depleted by three rounds of absorption on plastic dishes;antibody and in development of a normal GC. Thus, our
nonadherent cells were stained with FITC-conjugated F(ab9)2 goat
results indicate an obligatory role of B cell complement anti-mouse IgM (GamIgM) and counterstained with either PE-conju-
receptors in responses to protein antigens. gated anti-CD5 MAb (Ly-1), PE-conjugated anti-CD11b mAb (Mac-1)
or both, or with PE-conjugated anti-CD23 MAb (low affinity IgE Fc
receptor). Results presented are pooled splenic MNCs or peritonealExperimental Procedures
cells from two mice for each group. Single cell suspensions from
erythrocyte-depleted peripheral blood were stained with FITC-con-Construction of Cr22/2 Mice
A genomic clone that included 12 kb of the 39 end of the Cr2 locus jugated CD19 MAb (1D3, provided by Dr. D. Fearon, University of
Cambridge, United Kingdom) and counterstained with biotinylatedwas isolated from a strain 129 library (isogenic to ES cells) and
subcloned in pBluescript (Stratagene, La Jolla, CA). The targeting MAb 7G6 coupled to streptavidin±PE. All of the rat antibodies were
purchased from Pharmingen (San Diego, CA). Isotype-matched ratvector pNT/Cr2 was constructed in two steps by inserting genomic
fragments, i.e., 3 kb HincII±BamHI and 3.5 kb BamHI±EcoRI, on IgGs (Caltag Laboratories, South San Francisco, CA) were used as
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isotype controls for nonspecific staining. Stained cells were ana- cells developed by Dr. P. Lane and colleagues) cross-linked with
1 mg/ml anti-CD8 (obtained from the 53-6-72 hybridoma cell linelyzed on a FACSTAR Plus (Becton Dickinson, Mountain View, CA);
at least 50,000 events were analyzed for each sample. provided by Dr. D. Parker). Alternatively, combinations of 10 mg/ml
of F(ab9)2 fragments of GamIgM and soluble CD40L, or CD40L and
IL-4 (100 IU/ml, provided by Dr. A. Marshak-Rothstein, Boston Uni-Immunohistochemistry
versity) were used to activate the cells. For LPS stimulation, B cellsImmunohistochemical staining of spleen sections was performed
were activated with 0.05±25 mg/ml of LPS (Salmonella typhimurium,as described by Han et al. (1995). Spleens of 6- to 8-week-old
Sigma). After 48 hr, 0.5 mCi/ml [3H]thymidine (Amersham Corpora-nonimmune mice, or spleens of Cr22/2 mice and wild-type lit-
tion, Arlington Hights, IL) was added, and 6 hr later, cells weretermates that had been challenged 7 days earlier with 3 3 107 pfu
harvested onto glass fiber filter strips (Cambridge Technology, In-of bacteriophage FX174, were snap frozen in Tissue-Tek OCT com-
corporated, Watertown, MA) and cellular [3H]thymidine incorpora-pound (Miles, Incorporated, Elkhart, IN) by immersion in a bath of
tion determined in a liquid scintillation counter (Beckman, model2-methylbutane cooled in liquid nitrogen and stored at 2708C. Serial
LS5000TD).4 mm sections were cut on a cryostat microtome, thaw-mounted
onto poly-L-lysine (Sigma Chemicals, St. Louis, MO)-coated slides,
fixed in cold acetone for 10 min, rehydrated in PBS (pH 7.4) for 10
Statistics
min., and blocked with PBS, 5% BSA, 0.1% Tween-20, 5% rabbit
Student's t test was used to evaluate differences between the anti-
serum, and 1 mg of CD32/CD16 MAb (2.4G2) for 20 min at room
body and GC responses of Cr22/2 versus wild-type controls. Differ-
temperature. Splenic sections from immune and nonimmune mice
ences were considered statistically significant when p < 0.05.
were incubated with biotinylated CD35/CD21 MAb (7E9), with biotin-
ylated CD45R MAb (B220), or with biotinylated IgG2a (isotype con-
trol) followed by an incubation step with avidin±alkaline phospha- Acknowledgments
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